Baudax Bio (BXRX) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights
August 5, 2021 7:00 AM EDTTotal Number of ANJESO® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020
ANJESO® Demand Showing Strong Growth Based on Several Key Quarter-Over-Quarter Metrics (Second Quarter of 2021 Compared to First Quarter of 2021);
 Total Number of Vials Sold to All Customers Up 30%  Vials Sold to Hospitals and ASCs Combined Up 46%  Vials Sold to Existing Hospitals Up 55%  Vials Sold to New Ambulatory Surgery Centers Up 150%
Formulary Wins: 82% Success Rate at P&T... More
